Screener
Inhibrx Biosciences, Inc. INBX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
| Line item | MARCH 31, 2026 | DECEMBER 31, 2025 |
|---|---|---|
| Accounts payable | $8,762 | $5,944 |
| Accrued expenses | 15,342 | 25,529 |
| Current portion of operating lease liability | 2,408 | 2,326 |
| Total current liabilities | 26,512 | 33,799 |
| Long-term debt, net | 174,994 | 100,559 |
| Non-current portion of operating lease liability | 3,496 | 4,127 |
| Total liabilities | 205,002 | 138,485 |
| Commitments and contingencies (Note 6) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s total current liabilities?
- Inhibrx Biosciences, Inc. (INBX) reported total current liabilities of $26.51M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s total current liabilities changed year-over-year?
- Inhibrx Biosciences, Inc.'s total current liabilities decreased by 39.2% year-over-year, from $43.64M to $26.51M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s total current liabilities?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s total current liabilities has grown at a -22.5% compound annual growth rate (CAGR), from $56.31M to $33.8M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Inhibrx Biosciences, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude